A II) and angiotensin II (A II) on blood pressure and aldosterone production in man under conditions of normal and low sodium (Na) intake. Seven normal male subjects in balance on constant normal Na intake ( 
INTRODUCTION
In the years after the studies of Laragh (1, 2) demonstrating that angiotensin II (A II)' is a potent stimulator of aldosterone secretion in man, the renin-angiotensinaldosterone cascade has become accepted as a coordinated system acting simultaneously to control blood pressure and sodium and potassium balance (3) . A II is degraded into supposedly inactive fragments by the action of aminopeptidases, endopeptidases, and carboxypeptidases (4) . Recently, however, the C-terminal hep-tapeptide fragment of A II, [des-Aspartyll]-angiotensin II ([des-Aspi-A II) was found to be an agonist in that it has strong affinity for adrenal cortical receptors and stimulates aldosterone biosynthesis in vivo in the sheep (5), rat (6) , rabbit (7) , and dog (8) and in vitro in the rat, rabbit, cat, and dog (9, 10) . On (11, 12) and essentially equivalent ability to suppress renin release from the kidney (13) . For these reasons, [des-Asp]-A II has been designated as "angiotensin III," a putative hormone of the renin-angiotensin system. This heptapeptide, [des-Asp]-A II, has been isolated and quantified from plasma of several species (14, 15) .
Restriction of dietary sodium intake decreases the pressor response and increases the sensitivity of the adrenal zona glomerulosa to A II and [des-Aspi-A II (16) . Recent studies have shown that adrenal cells from sodium-restricted rats increase maximal aldosterone production by 45% above cells from animals on normal sodium intake in response to either A II or [des-Aspi-A II. However, the increase in adrenal zona glomerulosa sensitivity to [des-Aspi-A II during sodium depletion is 10-fold greater than for A II (16) . This observation suggests that [des-Aspi-A II may mediate (at least in part) the enhanced response of the adrenal zona glomerulosa to sodium depletion.
To date, in vitro data have been consistent with an action of A II and [des-Asp]-A II at the same receptor sites in the zona glomerulosa (17) (18) (19) . However, a recent study (20) 
METHODS
Human subjects and study protocol. Seven normal white male volunteer subjects, 24-30 yr, with normal arterial blood pressures and no history of renal disease were studied. The subjects were given a constant diet containing 150 meq of sodium, 60 meq of potassium, 1 g of protein/kg, and 2,860 calories/day for 5 days at the Clinical Research Center before the study. Consecutive 24-h urine samples were collected for the first 4 days of the diet and consecutive 12-h urine samples were collected for the remainder of each study and were analyzed for sodium, potassium, and creatinine. No food was given after midnight before study day 1 when the subjects assumed the supine position until completion of the study. At 6:15 a.m. on study day 1, the subjects completed their 12-h urine collections without arising. A heparin lock for obtaining blood samples was placed in the left antecubital vein and an intravenous infusion of5% dextrose in water (D5W) at 1 ml/min was begun in the right antecubital vein. At 6:30 a.m., blood pressure monitoring with an Arteriosonde (Medical Electronics Division, Hoffman-LaRoche Inc., Cranbury, N. J.) was begun and was continued every 2 min until completion ofthe study. At 7:00 and 7:30 a.m., control blood samples were obtained for the determination of plasma sodium, potassium, cortisol, and aldosterone. After completion ofblood sampling at 0730 hours, an intravenous infusion of [des-Asp]-A II at either 2,4, or 6 pmol/ kg per min was begun. Thereafter, blood sampling was accomplished at 15-min intervals until completion ofeach study at 9:00 a.m. The heptapeptide, [des-Asp]-A II, was infused at three successively increasing dose levels ranging from 2 to 18 pmol/kg per min and maintained for 30 min at each dose level. The total duration of infusion for each subject was 90 min; blood samples for the estimation of plasma renin activity also were obtained at 0 and 90 min of infusion.
After completion of the infusion at 9:00 a.m., the subjects continued on the constant diet and 12-h urine collections. On study day 2, an identical protocol as for study day 1 was followed except that instead of [des-Aspi-A II, A II at 2,4, and 6 pmol/kg per min (30 min at each dose level) was administered. The diet was discontinued, and the subjects were discharged from the Clinical Research Center after completion of the final 12-h urine collection at 6:30 p.m. on study day 2. The total volume of blood obtained from each subject during the two study days was 220 ml.
After an interval of4 wk on an ad lib. diet, the same subjects were placed on a constant diet containing 10 meq of sodium, 60 (5, 6, 12, 17) . The [Asn1, Val5]-A II was not contaminated with [des-Aspi-A II as demonstrated by thin-layer chromatography in a system of butanol, acetic acid, water, and puridine. These peptides were diluted in sterile H20, filtered with 0.22-gm millipore filter (Millipore Corp., Bedford, Mass.), and stored at 40C in sterile vials for 1-6 wk at a concentration of 50 ,ug/ml.
Animal in vivo and in vitro studies. Random aliquots of the sterilized preparations of the peptides infused into man were assayed subsequently for pressor activity in the anesthetized rat and steroidogenesis in adrenal cortical cell suspensions from rabbits and rats.
Male Wistar rats (200-300 g) were housed individually in metabolic cages in a temperature-controlled room (20-22°C) illuminated between 8 a.m. and 8 p.m. and were maintained on low sodium rat chow (General Biochemicals, Grand Island Biologicals, Chagrin Falls, Ohio) and 0.5% saline solution ad lib. to insure normal sodium intake.
A group of rats on normal sodium diet were anesthetized with intraperitoneal pentobarbital sodium (60 mg/kg). The iliac artery and femoral vein were cannulated with PE-50 intramedic tubing. A bilateral nephrectomy was performed, and the animals were allowed a 3-to 4-h equilibration period so that endogenous levels of renin and angiotensin were as low as possible without risking postnephrectomy changes in vascular reactivity. Arterial blood pressures were monitored through the arterial cannula via a Statham P23D pressure transducer (Statham Instruments Div. Gould Inc., Oxnard, Calif.) connected to a Brush Mark 220 recorder (Instrument Systems Division, Gould Inc., Cleveland, Ohio). 10 rats per group (five groups) were decapitated, and the adrenal glands removed rapidly. The medulla and inner cortex were removed from each gland, and the cells of the capsular layers were dispersed. The capsular tissue was minced and incubated in Krebs-Ringer bicarbonate buffer containing 0.2% D-glucose, 0.025% trypsin, 4% bovine serum albumin (BSA), and 0.005% deoxyribonuclease (1 ml buffer/20 mg tissue wet wt). After incubation for 15 min in a Dubnoff metabolic shaker under an atmosphere of 95% 02-5% CO2 at 60 rpm, the tissue was washed twice with Krebs-Ringer bicarbonate buffer containing 0.05% trypsin inhibitor, 0.2% D-glucose, 0.005% deoxyribonuclease, and 4% BSA (0.5 ml/20 mg tissue). Next, the tissue was dissociated by incubation in Krebs-Ringer bicarbonate buffer with 0.2% D-glucose, 0.02% collagenase, 0.05% trypsin inhibitor, 4% BSA, and 0.005% deoxyribonuclease (0.5 ml buffer/20 mg tissue) for 20 min in a Dubnoff metabolic shaker (10 rpm) under a 95% 02-5% CO2 atmosphere. The enzyme-treated tissue was dispersed by pipetting. The preparation was then incubated for 10 min, and the suspension was filtered through 150 ILm2 nylon mesh. The filtrate was centrifuged, and the pellet was washed three times and resuspended in KrebsRinger bicarbonate buffer with 0.2% D-glucose and 4% BSA. The number of viable cells present in the suspension was determined by exclusion staining with nigrosin and counting, using a Neubauer hemocytometer.
The cell suspensions were preincubated in the Dubnoff metabolic shaker for 30 min at 37°C in an atmosphere of 95% 02-5% CO2. All compounds were added to a 10-.d vol, and 10 ,ul of vehicle was administered to control.
Incubations lasting 60 min were used to determine dosedependent steroidogenic responses.
The adrenal glands of male New Zealand white rabbits (2-3 kg) that were killed by cervical dislocation also were used to prepare capsular adrenal zona glomerulosa cell suspensions in an identical manner as used for rat suspensions.
The incubations were terminated by adding 2 ml of 99% acetone to the experimental samples. The supernatant fraction was decanted and retained, and the pellet was resuspended in 80% acetone and centrifuged. The two supernatant fractions were pooled and evaporated to aqueous phase under a stream of N2 at 40°C. Aldosterone was purified by extraction into dichloromethane and by Sephadex (Pharmacia Fine Chemicals, Piscataway, N. J.) LH-20 column chromatography and was estimated by radioimmunoassay.
Analytical methods. All blood samples were collected on ice, centrifuged immediately, and the plasma was separated and frozen until the time for assay. Samples for plasma renin activity and aldosterone utilized EDTA as the anticoagulant; heparin was used in the samples for cortisol.
Plasma sodium and potassium were measured by flame photometry (model 143, Instrumentation Laboratory, Inc., Lexington, Mass.). Aldosterone was measured by the radioimmunoassay method of Buhler et al. (21) . After incubation, plasma renin activity was determined by radioimmunoassay of angiotensin I generated as described by Sealey et al. (22) . Plasma cortisol was measured by the fluorometric method of Mattingly (23) .
Statistical analysis. The results are expressed as mean± 1 SE. Statistical analysis was carried out with the doubletailed Student's t test for paired data, and P values of <0.05 are considered significant.
RESULTS [des-Asp ]-A II and A II infusion studies in man
Characteristics of subjects on normal and low sodium intake. The characteristics of the subjects in sodium balance on the fifth day of normal (150 meq/day) and low (10 meq/day) sodium intake are summarized in Table I . Sodium restriction with iso- caloric intake was not associated with significant weight reduction. On each diet, 24-h urinary sodium output closely matched intake, and 24-h urinary potassium excretion was unchanged in the presence of a constant 60-meq/day potassium intake. In the process of achieving sodium balance on the low sodium intake, the subjects acquired a cumulative sodium deficit of 187+15 meq. Serum sodium and potassium concentrations were unchanged by dietary sodium intake. Systolic blood pressure tended to be slightly lower when the subjects were on low sodium intake. Restriction of dietary sodium intake was associated with a highly significant increase in plasma renin activity and aldosterone concentration (P < 0.001 and P < 0.005, respectively). A 4.5-fold rise in plasma renin activity was associated with a 6.5-fold increase in plasma aldosterone concentration.
Responses to [des-Asp ]-A II infusion during normal sodium intake (Fig. 1) Responses to A II infusion during normal sodium intake (Fig. 3) Plasma aldosterone concentration was 8.7±2.5 ng/100 ml at -30 min and 7.0+2.2 ng/100 ml (P = NS) at 0 min. A II infusion resulted in an increase in plasma aldosterone to 11.7±1.7 ng/100 ml by 15 min of the 2-pmol/kg per min dose. Thereafter with time and higher dose of A II, plasma aldosterone concentration increased in a step-wise fashion to 26.8 ±2.0 ng/100 ml (P < 0.005) with 6 pmol/kg per min at the end of the infusion.
Plasma cortisol concentration was 20.7+3.6 ng/100 ml at -30 min and 18.3±3.4 ng/100 ml (P = NS) at 0 min. A II infusion did not alter plasma cortisol levels significantly at any time or dose. Similarly, plasma potassium concentration remained constant during the A II infusion.
Plasma renin activity was 2.06±0.28 ng/ml per h in the control period and was decreased to 1.08±0.09 ng/ml per h (P < 0.01) by the termination of the A II infusion.
Responses to A II infusion during low sodium intake (Fig. 4) AT EACH DOSE LEVEL ninutes FIGURE 3 Blood pressure and aldosterone responses to A II infusion of subjects during normal sodium intake. Each subject received three cumulative doses of octapeptide. *, values significantly different from zero control values (P < 0.05); **, P < 0.01. min. A II infusion produced no change (from base line) in plasma cortisol or potassium levels in sodiumdepleted subjects. Plasma renin activity was 9.40+1.05 ng/ml per h in the control period and was decreased to 4.87+0.68 ng/ml per h (P < 0.001) by the end of the A II infusion.
Comparison of the effects of the angiotensin peptides on blood pressure of subjects during normal and low sodium intake (Fig. 5) Comparison of the effect ofthe angiotensin peptides on aldosterone production of subjects during normal and low sodium intake (Fig. 6) . With During low sodium intake, [des-Aspi-A II also had less pressor activity and A II at each peptide dose (P < 0.01).
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.1 ng/100 at the 2-and 6-pmol/kg per min dose levels, respectively. On the other hand, A II produced an increase in the aldosterone level of 31.7±8.7 and 63.5 ±9.7 ng0100 ml with the two doses, respectively. Low sodium intake increased the increment in aldosterone production induced by [des-Asp]-A II at both dose levels: 0.5±1.1 vs. 16.8±8.6 ng/100 ml (P < 0.05) at 2 pmol/kg per min and 5.8±2.0 vs. 15.9±5.1 ng/100 ml (P < 0.05) at 6 pmol/kg per min. Sodium deprivation sensitized the adrenal zona glomerulosa to [des-Asp]-A II more than to A II at the 2-pmol/kg per min dose, when [des-Aspi-A II had 62% ofthe aldosterone-stimulating activity of A II. However, there was a plateau in the dose-response curve of the heptapeptide, so that [des-Aspi-A II had only 29% of the steroidogenic activity of the octapeptide at 6 pmol/kg per min. Low sodium intake increased the increment in aldosterone production in response to A II at the 2-pmol/kg per min dose level (8.3±3.4 vs. 29.6±9.3 ng/100 ml, P < 0.05) and at the 6-pmol/kg per min dose level (19.0±2.6 vs. 63.5+9.7 ng/100 ml, P < 0.005). pmol/kg/min FIGURE 6 Comparison of the effect of the angiotensin peptides on aldosterone production of subjects during normal and low sodium intake. Dietary sodium deprivation in man is followed by enhanced activity of the renin-angiotensin-aldosterone system as manifested by increased plasma renin activity and aldosterone secretion and excretion (1, 3, 27) . In the present study, as reported by others (25, 27) , vascular sensitivity to A II decreased significantly when sodium intake was restricted. The pressor response to infused A II in subjects on low sodium intake was reduced to 62-68% of the pressor response obtained on normal sodium intake. In contrast, however, low sodium intake increased the pressor activity of [des-Aspi-A II at the initial and lowest dose of 2 pmol/kg per min. However, with progressively higher doses of [des-Aspi-A II, we observed a progressive and significant decrease in vascular sensitivity during sodium depletion. At (28) . The octapeptide analogue, however, effectively inhibits vascular smooth muscle and blood pressure responses to both peptides (16, 29) . In the present study, [des-Aspi-A II and A II administration under normal conditions of sodium balance resulted in predominance of vascular smooth muscle and adrenal cortical responses to the octapeptide. These results differ from those of animal studies showing that the heptapeptide displays greater affinity for the adrenal zona glomerulosa and, thus, for stimulation of aldosterone secretion. During sodium restriction in man, however, the adrenal cortex was sensitized more to the action of the heptapeptide than to the octapeptide at the initial dose of 2 (13, 30) in the dog and Steele and colleagues (7) in the rabbit. The mechanism of the inhibitory effect on renin secretion is not understood completely, but the data are consistent with feedback inhibition of the peptide at the juxtaglomerular apparatus (31, 32) . A renal hemodynamic mechanism also is possible, but the marked differences in renal vasoconstrictor effects of the octapeptide and heptapeptide in the rabbit, dog, and isolated, perfused rat kidney (33) do not account for equivalent suppression of renin secretion by the two peptides. As well, it is unlikely that renin suppression is due to an effect of the peptides on sodium delivery to the distal tubule or sodium transport in the ascending limb of the loop of Henle because the degree of renin suppression is independent of changes in renal sodium excretion (7, 30) . Because we did not assess renal hemodynamics and sodium excretion in response to [des-Aspi-A II, the contribution of these mechanisms to the observed renin suppression in man remains to be clarified.
Animal in vivo and in vitro studies
The most striking finding of the present study is the difference in dose-response curves to A II and [des-Asp]-A II in man. In the sodium-depleted subjects, increasing doses of A II produce a stepwise increase in blood pressure and aldosterone production. The initial dose of [des-Asp]-A II results in a rise in blood pressure and aldosterone production. However, with progressively higher doses of [des-Asp]-A II, a plateau of blood pressure and aldosterone production occurs. A similar, less dramatic difference in doseresponse curves with the two peptides also was observed in the sodium-repleted subjects. The doseresponse curves are not parallel and although no 
